We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
Cap. Flow
-$5.51M
Cap. Flow %
-4.87%
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19

Top Buys

Rank Stock Value
1
FNCL icon
Fidelity MSCI Financials Index ETF
FNCL
+$1.46M
2
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.13M
3
MNOV icon
MediciNova
MNOV
+$969K
4
ADVM
Adverum Biotechnologies
ADVM
+$866K
5
CLSD
Clearside Biomedical
CLSD
+$856K

Top Sells

Rank Stock Value
1
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$2.78M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$1.32M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.22M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$1.01M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$938K

Sector Composition

Rank Sector Weight
1 Healthcare 77.9%
2 Financials 0.8%
3 Technology 0.58%
4 Consumer Discretionary 0.4%
5 Energy 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$13.9B
$799K 0.71%
37,132
+2,653
+8% +$54.9K
IMMU
27
DELISTED
Immunomedics Inc
IMMU
$799K 0.71%
33,761
-26,601
-44% -$535K
REGN icon
28
Regeneron Pharmaceuticals
REGN
$68.8B
$798K 0.71%
2,313
-39
-2% -$12.2K
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
$797K 0.7%
+36,223
New +$832K
CBIO
30
Crescent Biopharma
CBIO
$602M
$797K 0.7%
494
+29
+6% +$49.9K
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$796K 0.7%
+20,154
New +$639K
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$795K 0.7%
20,810
-5,308
-20% -$197K
KURA icon
33
Kura Oncology
KURA
$922M
$794K 0.7%
43,633
-11,650
-21% -$197K
IOVA icon
34
Iovance Biotherapeutics
IOVA
$2.23B
$793K 0.7%
61,951
-28,975
-32% -$424K
PRTA icon
35
Prothena Corp
PRTA
$458M
$793K 0.7%
54,358
+33,902
+166% +$670K
AKCA
36
DELISTED
Akcea Therapeutics Inc
AKCA
$790K 0.7%
33,315
-6,036
-15% -$144K
LGND icon
37
Ligand Pharmaceuticals
LGND
$6.02B
$787K 0.7%
6,091
-4,763
-44% -$531K
GTHX
38
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$787K 0.7%
18,103
-20,022
-53% -$858K
LOXO
39
DELISTED
Loxo Oncology, Inc
LOXO
$787K 0.7%
4,535
-4,811
-51% -$723K
PBYI icon
40
Puma Biotechnology
PBYI
$406M
$784K 0.69%
13,252
+4,123
+45% +$239K
ONCE
41
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$784K 0.69%
9,477
-10,547
-53% -$814K
SRNE
42
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$783K 0.69%
+108,716
New +$740K
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
$780K 0.69%
17,249
-2,082
-11% -$94.8K
DCPH
44
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$779K 0.69%
+19,795
New +$583K
MRNS
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$778K 0.69%
27,498
+7,401
+37% +$164K
FAS icon
46
Direxion Daily Financial Bull 3x ETF
FAS
$2.4B
$776K 0.69%
12,324
-11,246
-48% -$737K
TGTX icon
47
TG Therapeutics
TGTX
$8.58B
$776K 0.69%
59,022
-30,898
-34% -$425K
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$774K 0.68%
+65,221
New +$813K
PVLA
49
Palvella Therapeutics
PVLA
$1.98B
$773K 0.68%
1,907
+336
+21% +$160K
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
$772K 0.68%
49,455
-9,381
-16% -$142K
1
2
3 4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2018 Portfolio in Review

As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.

Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.

  • Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
  • Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
  • Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
  • Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
  • Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
  • Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.

Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.